---
figid: PMC8468657__pharmaceutics-13-01500-g003
figtitle: 'Iterative Upgrading of Small Molecular Tyrosine Kinase Inhibitors for EGFR
  Mutation in NSCLC: Necessity and Perspective'
organisms:
- NA
pmcid: PMC8468657
filename: pharmaceutics-13-01500-g003.jpg
figlink: /pmc/articles/PMC8468657/figure/pharmaceutics-13-01500-f003/
number: F3
caption: 'The acquired resistance mechanisms to third-generation EGFR-TKIs can be
  classified as EGFR-dependent resistance and EGFR-independent resistance. The EGFR-dependent
  mechanism: EGFR re mutation, T790M deletion and EGFR amplification; The EGFR-independent
  mechanism: amplification of MET and HER2, mutation of RAS and BRAF, histological
  transformation, EMT, oncogene fusion, activation of the PI3K/Akt/mTOR pathway, PTEN
  deletion, abnormity of the FGFR signaling pathway, and the induction of angiogenesis.
  (MET: mitogen activation kinase; EMT: epithelial mesenchymal transition; PTEN: phosphatase
  and tensin homology; FGFR: fibroblast growth factor receptor; ERK: extracellular
  regulated protein kinases). Reprinted with permission from ref. []. Copyright 2018
  Elsevier Science.'
papertitle: 'Iterative Upgrading of Small Molecular Tyrosine Kinase Inhibitors for
  EGFR Mutation in NSCLC: Necessity and Perspective.'
reftext: Jing Zhu, et al. Pharmaceutics. 2021 Sep;13(9):1500.
year: '2021'
doi: 10.3390/pharmaceutics13091500
journal_title: Pharmaceutics
journal_nlm_ta: Pharmaceutics
publisher_name: MDPI
keywords: epidermal growth factor receptor tyrosine kinase inhibitors | EGFR mutations
  | molecular targeted therapy | non-small cell lung cancer | resistance mechanism
automl_pathway: 0.898609
figid_alias: PMC8468657__F3
figtype: Figure
organisms_ner:
- Drosophila melanogaster
- Homo sapiens
redirect_from: /figures/PMC8468657__F3
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC8468657__pharmaceutics-13-01500-g003.html
  '@type': Dataset
  description: 'The acquired resistance mechanisms to third-generation EGFR-TKIs can
    be classified as EGFR-dependent resistance and EGFR-independent resistance. The
    EGFR-dependent mechanism: EGFR re mutation, T790M deletion and EGFR amplification;
    The EGFR-independent mechanism: amplification of MET and HER2, mutation of RAS
    and BRAF, histological transformation, EMT, oncogene fusion, activation of the
    PI3K/Akt/mTOR pathway, PTEN deletion, abnormity of the FGFR signaling pathway,
    and the induction of angiogenesis. (MET: mitogen activation kinase; EMT: epithelial
    mesenchymal transition; PTEN: phosphatase and tensin homology; FGFR: fibroblast
    growth factor receptor; ERK: extracellular regulated protein kinases). Reprinted
    with permission from ref. []. Copyright 2018 Elsevier Science.'
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - Egfr
  - btl
  - htl
  - Mtor
  - Tor
  - Pi3K21B
  - Pi3K59F
  - Pi3K68D
  - Pi3K92E
  - Akt
  - Dif
  - dl
  - Rel
  - MKP-4
  - p38b
  - rl
  - Raf
  - Dsor1
  - Mtk
  - ras
  - Ras64B
  - Ras85D
  - CkIIbeta
  - Andorra
  - Anp
  - Acam
  - Erk7
  - Pten
  - EGFR
  - FGFR1
  - FGFR2
  - FGFR3
  - FGFR4
  - FGFRL1
  - ERBB2
  - HES1
  - RABGAP1L
  - MTOR
  - PIK3CA
  - PIK3CB
  - PIK3CD
  - PIK3CG
  - PIK3R3
  - PIK3R4
  - PIK3R5
  - PIK3R6
  - PIK3R1
  - PIK3R2
  - AKT1
  - AKT2
  - AKT3
  - NFKB1
  - MAPK1
  - MAPK3
  - MAPK11
  - MAPK12
  - MAPK13
  - MAPK14
  - MAPK8
  - MAPK9
  - MAPK10
  - ZHX2
  - ARAF
  - BRAF
  - RAF1
  - MAP2K7
  - MAP2K1
  - MAP2K2
  - GNA12
  - GNA13
  - KRAS
  - HRAS
  - NRAS
  - EGF
  - EPHB2
  - ITK
  - SLC22A3
  - PTEN
---
